Biocon Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

The approved drug is a biosimilar of the reference product Stelara (Ustekinumab).

Ustekinumab, a monoclonal antibody, is approved for the treatment of psoriasis vulgaris and psoriatic arthritis (PsA).

The biosimilar Ustekinumab has been developed and manufactured by the company and will be commercialized and marketed in Japan by the company’s exclusive commercial partner, Yoshindo Inc.

In August this year, Biocon Biologics had entered into a settlement and licensing agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (collectively known as Janssen) to commercialize Ustekinumab in Japan, upon regulatory approval.

Biocon Biologics (BBL) is a fully integrated global biosimilars company and the subsidiary of Biocon.

Biocon is an innovation-led global biopharmaceuticals company engaged in the production of therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small-molecule APIs in India and several key global markets, as well as generic formulations in the US, Europe, & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development.

The company reported a consolidated net loss of Rs 16 crore in Q2 FY25 as against a net profit of Rs 126 crore in Q2 FY24. Revenue from operations rose by 4% YoY to Rs 3,590 crore during the quarter.

Powered by Capital Market - Live News

Biocon will hold a meeting of the Board of Directors of the Company on 30 January 2025.

Powered by Capital Market - Live News

Tacrolimus is an immunosuppressant used in the treatment of organ transplant patients, which reduces the body's ability to reject a transplanted organ.

The approval further adds to Biocon's portfolio of complex drug products and will be commercialised in the region expeditiously, it added.

Biocon is an innovation-led global biopharmaceuticals company engaged in the production of therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small-molecule APIs in India and several key global markets, as well as generic formulations in the US, Europe, & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development.

The company reported a consolidated net loss of Rs 16 crore in Q2 FY25 as against a net profit of Rs 126 crore in Q2 FY24. Revenue from operations rose by 4% YoY to Rs 3,590 crore during the quarter.

Shares of Biocon shed 0.68% to Rs 370.40 on the BSE.

Powered by Capital Market - Live News

Biocon issued a statement stating that Biocon Biologics has fulfilled its obligations towards all deferred milestones under the acquisition agreement with Viatris. This also marks, as full and final remittance of considerations from Biocon Biologics toward Viatris for the acquisition.

Powered by Capital Market - Live News